Previous Close | 0.9000 |
Open | 0.8800 |
Bid | 0.8699 x 400 |
Ask | 0.8838 x 400 |
Day's Range | 0.8400 - 0.9222 |
52 Week Range | 0.4100 - 1.1200 |
Volume | |
Avg. Volume | 1,615,518 |
Market Cap | 162.52M |
Beta (5Y Monthly) | 0.86 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -1.4500 |
Earnings Date | May 07, 2024 - May 13, 2024 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 2.00 |
Nektar Therapeutics (Nasdaq: NKTR) management is scheduled to present at the upcoming H.C. Wainwright 2nd Annual Autoimmune & Inflammatory Disease Virtual Conference on Thursday, March 28, 2024 at 1:30 p.m. Eastern Time / 10:30 a.m. Pacific Time.
The placebo-controlled, phase IIb study will investigate the efficacy and safety of Nektar's (NKTR) rezpeg in patients with severe to very severe alopecia areata.
Nektar (NKTR) reports a wider-than-expected loss in the fourth quarter of 2023 while revenue beat estimates.